Volume 61, Issue 3

Combining Multiple Comparisons and Modeling Techniques in Dose‐Response Studies

F. Bretz

Corresponding Author

Novartis Pharma AG, Lichtstrasse 35, Basel, Switzerland

email:frank.bretz@novartis.comSearch for more papers by this author
J. C. Pinheiro

Novartis Pharmaceuticals, One Health Plaza, East Hanover, New Jersey 07936, U.S.A.

Search for more papers by this author
M. Branson

Novartis Pharma AG, Lichtstrasse 35, Basel, Switzerland

Search for more papers by this author
First published: 31 August 2005
Citations: 191

Abstract

Summary The analysis of data from dose‐response studies has long been divided according to two major strategies: multiple comparison procedures and model‐based approaches. Model‐based approaches assume a functional relationship between the response and the dose, taken as a quantitative factor, according to a prespecified parametric model. The fitted model is then used to estimate an adequate dose to achieve a desired response but the validity of its conclusions will highly depend on the correct choice of the a priori unknown dose‐response model. Multiple comparison procedures regard the dose as a qualitative factor and make very few, if any, assumptions about the underlying dose‐response model. The primary goal is often to identify the minimum effective dose that is statistically significant and produces a relevant biological effect. One approach is to evaluate the significance of contrasts between different dose levels, while preserving the family‐wise error rate. Such procedures are relatively robust but inference is confined to the selection of the target dose among the dose levels under investigation. We describe a unified strategy to the analysis of data from dose‐response studies which combines multiple comparison and modeling techniques. We assume the existence of several candidate parametric models and use multiple comparison techniques to choose the one most likely to represent the true underlying dose‐response curve, while preserving the family‐wise error rate. The selected model is then used to provide inference on adequate doses.

Number of times cited according to CrossRef: 191

  • Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder, Annals of Neurology, 10.1002/ana.25680, 87, 3, (347-356), (2020).
  • Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder, Neurology, 10.1212/WNL.0000000000009475, 94, 21, (e2222-e2232), (2020).
  • Comparison of hierarchical EMAX and NDLM models in dose-response for early phase clinical trials, BMC Medical Research Methodology, 10.1186/s12874-020-01071-2, 20, 1, (2020).
  • Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease, Gastroenterology, 10.1053/j.gastro.2020.01.047, (2020).
  • Statistical considerations on implementing the MCP-Mod method for binary endpoints in clinical trials, Contemporary Clinical Trials Communications, 10.1016/j.conctc.2020.100641, (100641), (2020).
  • Dose-Response Mixed Models for Repeated Measures – a New Method for Assessment of Dose-Response, Pharmaceutical Research, 10.1007/s11095-020-02882-0, 37, 8, (2020).
  • Grouping of endocrine disrupting chemicals for mixture risk assessment – Evidence from a rat study, Environment International, 10.1016/j.envint.2020.105870, 142, (105870), (2020).
  • Statistical Data Mining of Clinical Data, Quantitative Methods in Pharmaceutical Research and Development, 10.1007/978-3-030-48555-9, (225-315), (2020).
  • Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension, Hypertension, 10.1161/HYPERTENSIONAHA.119.14504, (2020).
  • Design optimization for dose-finding trials: a review, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2020.1730874, (1-12), (2020).
  • Efficient adaptive designs for clinical trials of interventions for COVID-19, Statistics in Biopharmaceutical Research, 10.1080/19466315.2020.1790415, (1-26), (2020).
  • Sample Size Allocation in Multiregional Dose-Finding Study Using MCP-Mod, Statistics in Biopharmaceutical Research, 10.1080/19466315.2020.1752298, (1-10), (2020).
  • A multiple comparison procedure for dose‐finding trials with subpopulations, Biometrical Journal, 10.1002/bimj.201800111, 62, 1, (53-68), (2019).
  • Generalized multiple contrast tests in dose‐response studies, Statistics in Medicine, 10.1002/sim.8444, 39, 6, (757-772), (2019).
  • On Optimal Designs for Clinical Trials: An Updated Review, Journal of Statistical Theory and Practice, 10.1007/s42519-019-0073-4, 14, 1, (2019).
  • Equivalence of regression curves sharing common parameters, Biometrics, 10.1111/biom.13149, 76, 2, (518-529), (2019).
  • Ligelizumab for Chronic Spontaneous Urticaria, New England Journal of Medicine, 10.1056/NEJMoa1900408, 381, 14, (1321-1332), (2019).
  • A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity, Science Translational Medicine, 10.1126/scitranslmed.aar6584, 11, 489, (eaar6584), (2019).
  • Bayesian hierarchical EMAX model for dose‐response in early phase efficacy clinical trials, Statistics in Medicine, 10.1002/sim.8167, 38, 17, (3123-3138), (2019).
  • Study design aspects and inter‐subject variability in longitudinal clinical phase II dose‐finding trials, Pharmaceutical Statistics, 10.1002/pst.1921, 18, 2, (248-259), (2019).
  • Phase II Dose Finding, Statistical Methods in Biomarker and Early Clinical Development, 10.1007/978-3-030-31503-0, (301-320), (2019).
  • First use of cenerimod, a selective S1P 1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study , Lupus Science & Medicine, 10.1136/lupus-2019-000354, 6, 1, (e000354), (2019).
  • Dose–response relationship of perineural dexamethasone for interscalene brachial plexus block: a randomised, controlled, triple‐blind trial, Anaesthesia, 10.1111/anae.14650, 74, 8, (1001-1008), (2019).
  • Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double‐blind, placebo‐controlled trial, European Journal of Heart Failure, 10.1002/ejhf.1591, 21, 11, (1426-1433), (2019).
  • Statistics at FDA: Reflections on the Past Six Years, Statistics in Biopharmaceutical Research, 10.1080/19466315.2019.1571322, 11, 1, (1-12), (2019).
  • Commentary on “Statistics at FDA: Reflections on the Past Six Years”, Statistics in Biopharmaceutical Research, 10.1080/19466315.2018.1554506, 11, 1, (17-19), (2019).
  • New Insights in Computational Methods for Pharmacovigilance: E-Synthesis, a Bayesian Framework for Causal Assessment, International Journal of Environmental Research and Public Health, 10.3390/ijerph16122221, 16, 12, (2221), (2019).
  • An algorithm for computing profile likelihood based pointwise confidence intervals for nonlinear dose-response models, PLOS ONE, 10.1371/journal.pone.0210953, 14, 1, (e0210953), (2019).
  • E-Synthesis: A Bayesian Framework for Causal Assessment in Pharmacosurveillance, Frontiers in Pharmacology, 10.3389/fphar.2019.01317, 10, (2019).
  • Incorporating Innovative Techniques Toward Extrapolation and Efficient Pediatric Drug Development, Therapeutic Innovation & Regulatory Science, 10.1177/2168479019842541, (216847901984254), (2019).
  • Comparison of different approaches for dose response analysis, Biometrical Journal, 10.1002/bimj.201700276, 61, 1, (83-100), (2018).
  • BMA‐Mod: A Bayesian model averaging strategy for determining dose‐response relationships in the presence of model uncertainty, Biometrical Journal, 10.1002/bimj.201700211, 61, 5, (1141-1159), (2018).
  • Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis, Pharmaceutical Statistics, 10.1002/pst.1906, 18, 1, (39-53), (2018).
  • Power and sample size for dose‐finding studies with survival endpoints under model uncertainty, Biometrics, 10.1111/biom.12968, 75, 1, (308-314), (2018).
  • Leadership in Statistics: Increasing Our Value and Visibility, The American Statistician, 10.1080/00031305.2017.1336484, 73, 2, (109-116), (2018).
  • Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect Models, The AAPS Journal, 10.1208/s12248-018-0205-x, 20, 3, (2018).
  • Key Aspects of Modern, Quantitative Drug Development, Statistics in Biosciences, 10.1007/s12561-017-9203-2, 10, 2, (283-296), (2018).
  • dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials, Computer Methods and Programs in Biomedicine, 10.1016/j.cmpb.2018.01.023, 157, (163-177), (2018).
  • Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study, Journal of Crohn's and Colitis, 10.1093/ecco-jcc/jjy085, 12, 10, (1158-1169), (2018).
  • The consequences of exposure to mixtures of chemicals: Something from ‘nothing’ and ‘a lot from a little’ when fish are exposed to steroid hormones, Science of The Total Environment, 10.1016/j.scitotenv.2017.11.081, 619-620, (1482-1492), (2018).
  • Optimal designs for dose–response models with linear effects of covariates, Computational Statistics & Data Analysis, 10.1016/j.csda.2018.05.017, 127, (217-228), (2018).
  • Multiplicity Considerations in Clinical Trials, New England Journal of Medicine, 10.1056/NEJMra1709701, 378, 22, (2115-2122), (2018).
  • , , . . : . pages, ISBN: 9781498746106, Biometrical Journal, 10.1002/bimj.201800068, 60, 5, (1024-1025), (2018).
  • On Design and Analysis of Dose-Response Trials for Early Clinical Development, Biopharmaceutical Applied Statistics Symposium, 10.1007/978-981-10-7829-3_15, (377-403), (2018).
  • Perfluorohexane Sulfonate (PFHxS) and a Mixture of Endocrine Disrupters Reduce Thyroxine Levels and Cause Antiandrogenic Effects in Rats, Toxicological Sciences, 10.1093/toxsci/kfy055, 163, 2, (579-591), (2018).
  • Dynamic development paths for expanding a proof‐of‐concept study to explore dose range, Statistics in Medicine, 10.1002/sim.7840, 37, 22, (3244-3253), (2018).
  • Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy, Allergy, 10.1111/all.13478, 73, 9, (1812-1822), (2018).
  • Integrating dose estimation into a decision‐making framework for model‐based drug development, Pharmaceutical Statistics, 10.1002/pst.1841, 17, 2, (155-168), (2018).
  • Multiplicity-Adjusted Confidence Limits in Risk Assessment with Quantal Response Data, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2018.1452026, 28, 6, (1182-1192), (2018).
  • Data-Driven Prior Distributions for A Bayesian Phase-2 COPD Dose-Finding Clinical Trial, Statistics in Biopharmaceutical Research, 10.1080/19466315.2018.1462728, 10, 3, (166-175), (2018).
  • A Cautionary Note When a Dose-Ranging Study is Used for Proving the Concept, Statistics in Biosciences, 10.1007/s12561-018-9224-5, (2018).
  • Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes, The AAPS Journal, 10.1208/s12248-017-0166-5, 20, 1, (2017).
  • Assessing the similarity of dose response and target doses in two non‐overlapping subgroups, Statistics in Medicine, 10.1002/sim.7546, 37, 5, (722-738), (2017).
  • A Simple and Efficient Statistical Approach for Designing an Early Phase II Clinical Trial: Ordinal Linear Contrast Test, New Advances in Statistics and Data Science, 10.1007/978-3-319-69416-0_11, (179-196), (2017).
  • Additional Topics, Quantitative Decisions in Drug Development, 10.1007/978-3-319-46076-5_13, (191-207), (2017).
  • Choosing Metrics Appropriate for Different Stages of Drug Development, Quantitative Decisions in Drug Development, 10.1007/978-3-319-46076-5_6, (69-84), (2017).
  • Bayesian Approach, Phase II Clinical Development of New Drugs, 10.1007/978-981-10-4194-5_11, (205-223), (2017).
  • Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies, Allergy, Asthma & Clinical Immunology, 10.1186/s13223-017-0183-z, 13, 1, (2017).
  • Gatekeeping Strategies and Graphical Approaches in Clinical Trials with Hierarchically Structured Study Objectives: A Review, Japanese Journal of Biometrics, 10.5691/jjb.38.41, 38, 1, (41-78), (2017).
  • Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations, Biometrical Journal, 10.1002/bimj.201600084, 59, 4, (804-825), (2017).
  • Data Analysis for Dose-Ranging Trials with Continuous Outcome, Phase II Clinical Development of New Drugs, 10.1007/978-981-10-4194-5_9, (155-182), (2017).
  • Dose-ranging design and analysis methods to identify the minimum effective dose (MED), Contemporary Clinical Trials, 10.1016/j.cct.2017.08.005, 63, (59-66), (2017).
  • Data Analysis of Dose-Ranging Trials for Binary Outcomes, Phase II Clinical Development of New Drugs, 10.1007/978-981-10-4194-5_10, (183-204), (2017).
  • Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection, Journal of Pharmacokinetics and Pharmacodynamics, 10.1007/s10928-017-9550-0, 44, 6, (581-597), (2017).
  • Designing Dose-Response Studies with Desired Characteristics, Quantitative Decisions in Drug Development, 10.1007/978-3-319-46076-5_8, (105-121), (2017).
  • A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy, Journal of Psychopharmacology, 10.1177/0269881117722998, 31, 9, (1190-1203), (2017).
  • Understanding MCP‐MOD dose finding as a method based on linear regression, Statistics in Medicine, 10.1002/sim.7424, 36, 27, (4401-4413), (2017).
  • Editorial: Multiplicity issues in clinical trials, Statistics in Medicine, 10.1002/sim.7506, 36, 28, (4423-4426), (2017).
  • (Pentamethylcyclopentadienato)rhodium Complexes for Delivery of the Curcumin Anticancer Drug, European Journal of Inorganic Chemistry, 10.1002/ejic.201601331, 2017, 12, (1812-1823), (2017).
  • Combined exposure to low doses of pesticides causes decreased birth weights in rats, Reproductive Toxicology, 10.1016/j.reprotox.2017.05.004, 72, (97-105), (2017).
  • BGG492 as an adjunctive treatment in patients with partial‐onset seizures: A 12‐week, randomized, double‐blind, placebo‐controlled, phase II dose‐titration study with an open‐label extension, Epilepsia, 10.1111/epi.13771, 58, 7, (1217-1226), (2017).
  • Phase II dose–response trials: A simulation study to compare analysis method performance under design considerations, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2017.1293078, 27, 5, (885-901), (2017).
  • Bayesian penalized log-likelihood ratio approach for dose response clinical trial studies, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2017.1293081, 27, 6, (975-989), (2017).
  • Identification of the minimum effective dose for normally distributed data using a Bayesian variable selection approach, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2017.1295247, 27, 6, (1073-1088), (2017).
  • The role of adaptive trial designs in drug development, Expert Review of Clinical Pharmacology, 10.1080/17512433.2017.1321985, 10, 7, (727-736), (2017).
  • Adaptive Seamless Phase II/III Designs—Background, Operational Aspects, and Examples, Drug Information Journal, 10.1177/216847900604000412, 40, 4, (463-473), (2017).
  • A Mixed Effect Emax Model Applied for Determination of Malathion Optimal Dose, Avicenna Journal of Medical Biochemistry, 10.15171/ajmb.2017.08, 5, 1, (45-49), (2017).
  • Clinical dose–response for a broad set of biological products: A model-based meta-analysis, Statistical Methods in Medical Research, 10.1177/0962280216684528, (096228021668452), (2017).
  • Dose-biomarker-response modeling of the anticancer effect of ethaselen in a human non-small cell lung cancer xenograft mouse model, Acta Pharmacologica Sinica, 10.1038/aps.2016.114, 38, 2, (223-232), (2016).
  • A comparative study of the dose-response analysis with application to the target dose estimation, Journal of Statistical Theory and Practice, 10.1080/15598608.2016.1261260, 11, 1, (145-162), (2016).
  • Multiple confidence intervals for selected parameters adjusted for the false coverage rate in monotone dose–response microarray experiments, Biometrical Journal, 10.1002/bimj.201500254, 59, 4, (732-745), (2016).
  • Likelihood ratio tests for a dose‐response effect using multiple nonlinear regression models, Biometrics, 10.1111/biom.12563, 73, 1, (197-205), (2016).
  • Analysis of Clinical Dose–Response in Small-Molecule Drug Development: 2009–2014, Statistics in Biopharmaceutical Research, 10.1080/19466315.2016.1256229, 9, 2, (137-146), (2016).
  • A decision-theoretic phase I–II design for ordinal outcomes in two cycles, Biostatistics, 10.1093/biostatistics/kxv045, 17, 2, (304-319), (2016).
  • Dose-response meta-analysis of differences in means, BMC Medical Research Methodology, 10.1186/s12874-016-0189-0, 16, 1, (2016).
  • Applications and Case Studies, Group Sequential and Confirmatory Adaptive Designs in Clinical Trials, 10.1007/978-3-319-32562-0_11, (241-276), (2016).
  • Model selection versus model averaging in dose finding studies, Statistics in Medicine, 10.1002/sim.6991, 35, 22, (4021-4040), (2016).
  • Multiple comparison procedure and modeling: a versatile tool for evaluating dose–response relationships in veterinary pharmacology – a case study with furosemide, Journal of Veterinary Pharmacology and Therapeutics, 10.1111/jvp.12313, 39, 6, (539-546), (2016).
  • Current Practice on Multiplicity Adjustment and Sample Size Calculation in Multi-arm Clinical Trials, Therapeutic Innovation & Regulatory Science, 10.1177/2168479016651660, 50, 6, (846-852), (2016).
  • Biomarker informed add-arm design for unimodal response, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2015.1052474, 26, 4, (694-711), (2015).
  • A Flexible Bayesian Approach for Modeling Monotonic Dose–Response Relationships in Drug Development Trials, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2014.919931, 25, 1, (137-156), (2015).
  • Translational Science Biostatistics, Principles of Translational Science in Medicine, 10.1016/B978-0-12-800687-0.00029-3, (267-280), (2015).
  • Analysis of clinical trials with biologics using dose–time‐response models, Statistics in Medicine, 10.1002/sim.6551, 34, 22, (3017-3028), (2015).
  • Confidence bounds for nonlinear dose–response relationships, Statistics in Medicine, 10.1002/sim.6566, 34, 27, (3546-3562), (2015).
  • Testing effect of a drug using multiple nested models for the dose–response, Biometrics, 10.1111/biom.12276, 71, 2, (417-427), (2015).
  • Dose response signal detection under model uncertainty, Biometrics, 10.1111/biom.12357, 71, 4, (996-1008), (2015).
  • Characterization of dose‐response for count data using a generalized MCP‐Mod approach in an adaptive dose‐ranging trial, Pharmaceutical Statistics, 10.1002/pst.1693, 14, 4, (359-367), (2015).
  • From single chemicals to mixtures—Reproductive effects of levonorgestrel and ethinylestradiol on the fathead minnow, Aquatic Toxicology, 10.1016/j.aquatox.2015.10.009, 169, (152-167), (2015).
  • A Step-Up Test Procedure to Find the Minimum Effective Dose, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2014.920854, 25, 3, (525-538), (2014).
  • An Adaptive Staggered Dose Design for a Normal Endpoint, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2014.920862, 25, 4, (731-756), (2014).
  • See more

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.